Under the Microscope: Tony Keating, ResApp Health
About the author:
- Author name:
- By Iain Wilkie
- Job title:
- Associate Analyst
- Date posted:
- 30 March 2021, 4:00 PM
- Sectors Covered:
- Healthcare, Biotechnology, Medical Devices
I spoke with Chief Executive Officer and Managing Director of ResApp (ASX:RAP), Tony Keating recently. Tony provides an update on a number of recent news events.
Listen to the podcast
The Morgans Under the Microscope podcast series provides exclusive interviews with executives from some of the most exclusive ASX-listed healthcare companies, as well as weekly updates on the healthcare sector.
Listen to all our Under the Microscope podcasts
Find out more
Morgans clients can access further analysis by browsing the latest research on our client website. If you would like access or more information, please contact your adviser or you are also welcome to start a two-week trial of our online platform, which provides access to detailed market analysis and insights, provided by our award-winning research team.
Create trial account
Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.
Disclosure of interest: Morgans may from time to time hold an interest in any security referred to in this report and may, as principal or agent, sell such interests. Morgans may previously have acted as manager or co-manager of a public offering of any such securities. Morgans affiliates may provide or have provided banking services or corporate finance to the companies referred to in the report. The knowledge of affiliates concerning such services may not be reflected in this report. Morgans advises that it may earn brokerage, commissions, fees or other benefits and advantages, direct or indirect, in connection with the making of a recommendation or a dealing by a client in these securities. Some or all of Morgans Authorised Representatives may be remunerated wholly or partly by way of commission.
Print this page